Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 1, 2014
Pharmacy Choice - Pharmacy News - October 1, 2014

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
10/1/14 - FDA Approves Baxter's RIXUBIS [Coagulation Factor IX Recombinant] for Treatment of Children with Hemophilia B
By a News Reporter-Staff News Editor at Biotech Week-- Baxter International Inc. announced that the United States Food and Drug Administration has approved RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX..
10/1/14 - Hikma receives approval for colchicine 0.6mg capsules
Release date- 30092014- London,- Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application for colchicine 0.6 mg capsules by the US Food and Drug Administration. Hikma will market its colchicine under the brand name MITIGARE. Said Darwazah, Chairman and CEO of Hikma, sai
10/1/14 - Unisense FertiliTech Gets FDA Clearance for Its 'Compare & Select' Feature in EmbryoViewer Software [Health & Beauty Close - Up]
Unisense FertiliTech A/S reported that it has received FDA 510 clearance for its "Compare& Select" feature in the EmbryoViewer software. "We're excited to receive the FDA 510 clearance for the EmbryoViewer software, and believe this will aid IVF professionals in the selection of embryos that are likely to produce a live birth," said Vagn Rasmussen
9/30/14 - FDA Approves MOVANTIKâ?¢ naloxegol Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain
By a News Reporter-Staff News Editor at Cancer Weekly-- Nektar Therapeutics reported that partner AstraZeneca announced that the US Food and Drug Administration approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, in adult patients...
9/30/14 - Hikma Pharmaceuticals Gets FDA Approval For Colchicine Capsules
LONDON- Hikma Pharmaceuticals PLC Tuesday said it was granted approval by the US Food and Drug Administration for its colchicine 0.6 mg capsules for prophylaxis of gout flares in adults. According to IMS Health, sales of colchicine in the US market were approximately USD688 million for the 12 months ended August 2014, Hikma said in its statement Tu
9/30/14 - Par Pharmaceutical Begins Shipment of Generic Exforge®
Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity. According to IMS Health data, annual U.S. sales of Exforge ® are approximately $422 million. About Par Pharmaceutical Companies, Inc. Par Pharmaceutical Comp

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


The Diversion of Controlled Substances and the Law
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement